Biotage AB
STO:BIOT

Watchlist Manager
Biotage AB Logo
Biotage AB
STO:BIOT
Watchlist
Price: 155 SEK 2.58% Market Closed
Market Cap: 12.3B SEK
Have any thoughts about
Biotage AB?
Write Note

Biotage AB
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biotage AB
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Biotage AB
STO:BIOT
Total Current Liabilities
kr648m
CAGR 3-Years
31%
CAGR 5-Years
24%
CAGR 10-Years
20%
AddLife AB
STO:ALIF B
Total Current Liabilities
kr4.3B
CAGR 3-Years
35%
CAGR 5-Years
23%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Total Current Liabilities
kr847m
CAGR 3-Years
76%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genovis AB
STO:GENO
Total Current Liabilities
kr18.8m
CAGR 3-Years
12%
CAGR 5-Years
12%
CAGR 10-Years
13%
MedCap AB (publ)
STO:MCAP
Total Current Liabilities
kr331.9m
CAGR 3-Years
11%
CAGR 5-Years
6%
CAGR 10-Years
3%
M
Magle Chemoswed Holding AB
STO:MAGLE
Total Current Liabilities
kr68.3m
CAGR 3-Years
13%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
No Stocks Found

Biotage AB
Glance View

Market Cap
12.4B SEK
Industry
Life Sciences Tools & Services

Biotage AB engages in the provision of separation and synthesis technology solutions. The company is headquartered in Uppsala, Uppsala and currently employs 497 full-time employees. The company went IPO on 2000-06-30. Its customers include pharmaceutical and biotechnology companies, companies within the food industry and academic institutions. The firm offers systems and services within three areas: analytical chemistry, organic chemistry and industrial resins. Biotage’s offering within analytical chemistry consists of consumables with related applications to extract selected substances from various types of samples. The Company’s offering within organic chemistry includes products for pharmaceutical development based on both small molecules and peptides and its offering within industrial resins is composed of polymer-based resins and research services that lead to the development and manufacture of polymer-based materials. As of December 31, 2013, the Company operated 12 wholly owned subsidiaries worldwide.

BIOT Intrinsic Value
196.81 SEK
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Biotage AB's Total Current Liabilities?
Total Current Liabilities
648m SEK

Based on the financial report for Sep 30, 2024, Biotage AB's Total Current Liabilities amounts to 648m SEK.

What is Biotage AB's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
20%

Over the last year, the Total Current Liabilities growth was -11%. The average annual Total Current Liabilities growth rates for Biotage AB have been 31% over the past three years , 24% over the past five years , and 20% over the past ten years .

Back to Top